Galidesivir
Galidesivir (BCX4430), an adenosine analog originally developed for
human coronavirus (HCV), is currently undergoing early-stage clinical
studies examining its protection in healthy subjects and its
effectiveness against yellow fever, and has demonstrated antiviral
activity in preclinical studies against many RNA viruses, like SARS and
MERS2, and possibilities are that facilities with sufficient
bio-containment capabilities may screen Galidesivir against 2019-nCoV
[13] [15] [37].